Notice of Proposed Sale · 144
Dare Bioscience, Inc.
DARENASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- DARE BIOSCIENCE, INC.
- Issuer CIK
- 0001401914
- SEC file number
- 001-36395
- Phone
- (858) 926-7655
- Person for whose account securities are to be sold
- RASTETTER FAMILY TRUST
- Relationships to issuer
- Director
- Street
- 3655 Nobel Drive
- Street (continued)
- Suite 260
- City
- San Diego
- State / country code
- CA
- Postal code
- 92122
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 859 | 382.26 | 19,669,000 | 11/19/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 10/01/2016 | Board Comp. | Issuer | 148 | N | 10/01/2016 | Compensation |
| Common | 05/08/2007 | Various Private Investments in Cerulean - Pre-IPO | Issuer | 59 | N | 05/08/2007 | Cash |
| Common | 04/15/2014 | Various Private Investments in Cerulean - Pre-IPO | Issuer | 41 | N | 04/15/2014 | Cash |
| Common | 04/15/2014 | Various Private Investments in Cerulean - Pre-IPO | Issuer | 42 | N | 04/15/2014 | Cash |
| Common | 06/15/2011 | Various Private Investments in Cerulean - Pre-IPO | Issuer | 21 | N | 06/15/2011 | Cash |
| Common | 01/03/2017 | Board Comp. | Issuer | 6 | N | 01/03/2017 | Compensation |
| Common | 12/07/2007 | Various Private Investments in Cerulean - Pre-IPO | Issuer | 21 | N | 12/07/2007 | Cash |
| Common | 11/30/2012 | Various Private Investments in Cerulean - Pre-IPO | Issuer | 28 | N | 11/30/2012 | Cash |
| Common | 01/03/2017 | Board Comp. | Issuer | 203 | N | 01/03/2017 | Compensation |
| Common | 12/02/2011 | Various Private Investments in Cerulean - Pre-IPO | Issuer | 35 | N | 12/02/2011 | Cash |
| Common | 04/17/2014 | IPO | Issuer | 157 | N | 04/17/2014 | Cash |
| Common | 10/03/2016 | Board Comp. | Issuer | 4 | N | 10/03/2016 | Compensation |
| Common | 07/13/2009 | Various Private Investments in Cerulean - Pre-IPO | Issuer | 48 | N | 07/13/2009 | Cash |
| Common | 11/12/2010 | Various Private Investments in Cerulean - Pre-IPO | Issuer | 46 | N | 11/12/2010 | Cash |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 11/19/2026
- Signed
- /s/ William H Rastetter, Trustee
Company context
We are a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation we advance is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, we’re working to close critical gaps in care using science that serves her needs. In March 2025, we announced an expansion of our business model to include a dual-path approach to bringing new products to market. For select proprietary formulations, we are pursuing both traditional FDA approval and earlier market access via Section 503B compounding. We believe this strategy allows us to respond to clinician and patient demand for timely access while continuing to generate the data necessary to seek FDA approval and support long-term value creation. In addition to prescription-based offerings — both FDA-approved products and compounded drugs — we intend to bring to market select consumer health products that do not require a physician’s prescription, where appropriate based on product profile and market opportunity.